Literature DB >> 10818252

Effects of the CRF(1) receptor antagonist, CP 154,526, in the separation-induced vocalization anxiolytic test in rat pups.

J H Kehne1, S Coverdale, T C McCloskey, D C Hoffman, J V Cassella.   

Abstract

CRF(1) receptor antagonists have been proposed as novel pharmacological treatments for depression, anxiety and stress disorders. The primary goal of the present study was to evaluate the effects of the CRF(1) receptor antagonist, CP 154,526, in the separation-induced vocalization (SIV) model of anxiety. Nine- to 11-day-old rat pups were separated from their litter and the effects of intraperitoneally administered test compounds on the elicited ultrasonic vocalizations were measured. Side-effect potential was assessed using a modified inclined plane test ('time on an inclined plane', or TIP), and using negative geotaxis. SIV was reduced by CP 154,526 at doses that did not affect TIP or negative geotaxis, a profile like that of the 5-HT(1A) partial agonist buspirone. The benzodiazepine anxiolytic, diazepam, decreased SIV but also produced significant side effects at one to three-fold higher doses. Additional pharmacological characterization of SIV demonstrated anxiolytic-like effects of the atypical antipsychotic, clozapine, but not the typical antipsychotic, haloperidol, and of the serotonin reuptake inhibitor, zimelidine, but not the norepinephrine reuptake inhibitor, desipramine. In summary, the data support the conclusion that selective CRF(1) receptor antagonists may have utility in anxiety and stress disorders. The data further support the use of separation-induced vocalizations for identifying mechanistically diverse compounds with anxiolytic actions in man.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10818252     DOI: 10.1016/s0028-3908(00)00043-5

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  11 in total

Review 1.  Don't stress about CRF: assessing the translational failures of CRF1antagonists.

Authors:  Samantha R Spierling; Eric P Zorrilla
Journal:  Psychopharmacology (Berl)       Date:  2017-03-07       Impact factor: 4.530

Review 2.  Behavioral, biological, and chemical perspectives on targeting CRF(1) receptor antagonists to treat alcoholism.

Authors:  Eric P Zorrilla; Markus Heilig; Harriet de Wit; Yavin Shaham
Journal:  Drug Alcohol Depend       Date:  2013-01-05       Impact factor: 4.492

3.  Screening antidepressants in the chick separation-stress paradigm.

Authors:  Matthew W Feltenstein; Kenneth J Sufka
Journal:  Psychopharmacology (Berl)       Date:  2005-10-15       Impact factor: 4.530

4.  Acoustic characterization of ultrasonic vocalizations by a nocturnal primate Tarsius syrichta.

Authors:  Sharon Gursky-Doyen
Journal:  Primates       Date:  2013-04-03       Impact factor: 2.163

Review 5.  Progress in corticotropin-releasing factor-1 antagonist development.

Authors:  Eric P Zorrilla; George F Koob
Journal:  Drug Discov Today       Date:  2010-03-03       Impact factor: 7.851

6.  Characterization of the nociceptin receptor (ORL-1) agonist, Ro64-6198, in tests of anxiety across multiple species.

Authors:  G B Varty; L A Hyde; R A Hodgson; S X Lu; M F McCool; T M Kazdoba; R A Del Vecchio; D H Guthrie; A J Pond; M E Grzelak; X Xu; W A Korfmacher; D Tulshian; E M Parker; G A Higgins
Journal:  Psychopharmacology (Berl)       Date:  2005-09-29       Impact factor: 4.530

Review 7.  Therapeutic utility of non-peptidic CRF1 receptor antagonists in anxiety, depression, and stress-related disorders: evidence from animal models.

Authors:  John H Kehne; Christopher K Cain
Journal:  Pharmacol Ther       Date:  2010-09-06       Impact factor: 12.310

8.  The anxiolytic CRF(1) antagonist DMP696 fails to function as a discriminative stimulus and does not substitute for chlordiazepoxide in rats.

Authors:  Snjezana Lelas; Kim L Zeller; Kathryn A Ward; John F McElroy
Journal:  Psychopharmacology (Berl)       Date:  2003-02-18       Impact factor: 4.530

Review 9.  Developmental rodent models of fear and anxiety: from neurobiology to pharmacology.

Authors:  Despina E Ganella; Jee Hyun Kim
Journal:  Br J Pharmacol       Date:  2014-07-01       Impact factor: 8.739

10.  CRF-5-HT interactions in the dorsal raphe nucleus and motivation for stress-induced opioid reinstatement.

Authors:  Chen Li; Nicholas McCloskey; Jared Phillips; Steven J Simmons; Lynn G Kirby
Journal:  Psychopharmacology (Berl)       Date:  2020-11-24       Impact factor: 4.415

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.